ijms-logo

Journal Browser

Journal Browser

Molecular and Metabolic Insights into Liver Disease

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Endocrinology and Metabolism".

Deadline for manuscript submissions: closed (15 November 2024) | Viewed by 3020

Special Issue Editor


E-Mail Website
Guest Editor
1. Fundación Clínica Médica Sur, Ciudad de México, México
2. Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico
Interests: nonalcoholic steatohepatitis; hepatitis C; cholestasis; liver disease
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Chronic liver disease (CLD) is a major global health problem, affecting an estimated 844 million people worldwide. In fact, CLD caused by viral infections, alcohol/drug abuse, or metabolic disorders has increased mortality. These conditions lead to ongoing hepatocellular damage, culminating in liver fibrosis. The hepatocyte response to inflammation plays a crucial role in the pathophysiology of liver fibrosis, involving the recruitment of pro-inflammatory and anti-inflammatory cells, as well as the production of various cytokines and chemokines that stimulate hepatic stellate cells. Despite the substantial burden of CLD, the molecular mechanisms involved in the pathophysiology of liver disease that drive these conditions remain incomplete. Therefore, this issue aims to provide new insights into the cellular and molecular mechanisms involved in CLD.

Prof. Dr. Nahum Mendez-Sanchez
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • alcoholic liver disease
  • NAFLD
  • viral hepatitis
  • chronic liver disease
  • pathophysiology and treatment

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 4209 KiB  
Article
Bilirubin Molecular Species Play an Important Role in the Pathophysiology of Acute-on-Chronic Liver Failure
by Stephany M. Castillo-Castañeda, Jacqueline Cordova-Gallardo, Liliana Rivera-Espinosa, Juan L. Chavez-Pacheco, Mariana M. Ramírez-Mejía and Nahum Méndez-Sánchez
Int. J. Mol. Sci. 2024, 25(15), 8181; https://doi.org/10.3390/ijms25158181 - 26 Jul 2024
Cited by 3 | Viewed by 2741
Abstract
Bilirubin plays a key role in early diagnosis, prognosis, and prevention of liver diseases. Unconjugated bilirubin (UCB) requires conversion to a water-soluble form through liver glucuronidation, producing monoglucuronide (BMG) or diglucuronide bilirubin (BDG) for bile excretion. This study aimed to assess the roles [...] Read more.
Bilirubin plays a key role in early diagnosis, prognosis, and prevention of liver diseases. Unconjugated bilirubin (UCB) requires conversion to a water-soluble form through liver glucuronidation, producing monoglucuronide (BMG) or diglucuronide bilirubin (BDG) for bile excretion. This study aimed to assess the roles of bilirubin’s molecular species—UCB, BMG, and BDG—in diagnosing and understanding the pathogenesis of liver cirrhosis in patients with acute-on-chronic liver failure (ACLF), compensated liver cirrhosis (LC) patients, and healthy individuals. The study included patients with ACLF and compensated LC of diverse etiologies, along with healthy controls. We collected laboratory and clinical data to determine the severity and assess mortality. We extracted bilirubin from serum samples to measure UCB, BMG, and BDG using liquid chromatography–mass spectrometry (LC-MS). The quantification of bilirubin was performed by monitoring the mass charge (m/z) ratio. Of the 74 patients assessed, 45 had ACLF, 11 had LC, and 18 were healthy individuals. Among ACLF patients, the levels of molecular species of bilirubin were UCB 19.69 μmol/L, BMG 47.71 μmol/L, and BDG 2.120 μmol/L. For compensated cirrhosis patients, the levels were UCB 11.29 μmol/L, BMG 1.49 μmol/L, and BDG 0.055 μmol/L, and in healthy individuals, the levels were UCB 6.42 μmol/L, BMG 0.52 μmol/L, and BDG 0.028 μmol/L. The study revealed marked elevations in the bilirubin species in individuals with ACLF compared to those with compensated cirrhosis and healthy controls, underscoring the progression of liver dysfunction. The correlation of BMG and BDG levels with commonly used inflammatory markers suggests a relationship between bilirubin metabolism and systemic inflammation in ACLF. Full article
(This article belongs to the Special Issue Molecular and Metabolic Insights into Liver Disease)
Show Figures

Figure 1

Back to TopTop